补肺纳肾丸抑制PI3K/AKT/HIF-1通路调节细胞外基质沉积改善COPD进展
本研究探讨补肺纳肾丸(BFNSP)对慢性阻塞性肺疾病(COPD)的作用及机制。采用COPD大鼠模型,给予不同剂量BFNSP,通过肺功能、病理、ELISA、免疫组化、RT-qPCR和Western blotting检测,并进行体外细胞验证。结果显示BFNSP改善肺通气功能、减轻肺组织病理损伤、抑制炎症因子释放、减少细胞外基质沉积,并抑制PI3K/AKT/HIF-1信号通路激活(P<0.05)。
要点
- BFNSP可改善COPD大鼠肺通气功能并减轻肺组织病理损伤。
- BFNSP抑制COPD大鼠炎症因子释放和细胞外基质沉积。
- BFNSP通过抑制PI3K/AKT/HIF-1信号通路缓解COPD进展。
核心结论
- 补肺纳肾丸通过抑制PI3K/AKT/HIF-1信号通路调节细胞外基质沉积,从而改善COPD进展。
研究设计与样本
- 采用LC/MS分析BFNSP及其含药血清的主要成分;建立COPD大鼠模型,给予不同剂量BFNSP治疗;进行体外细胞实验验证。
主要发现
- BFNSP有效改善COPD大鼠肺通气功能状态,减轻肺组织病理损伤。
- BFNSP抑制炎症因子释放,减少细胞外基质沉积。
- BFNSP抑制肺组织中PI3K/AKT/HIF-1信号通路激活(P<0.05)。
临床怎么用
- BFNSP可能作为COPD的潜在治疗中药复方,其机制与抑制PI3K/AKT/HIF-1通路及调节细胞外基质沉积相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: According to the theory and practice of traditional Chinese medicine (TCM), chronic obstructive pulmonary disease (COPD) can be classified as "cough," "dyspnea," or "lung distention disease." Bufei Nashen pill (BFNSP) is a classic Chinese herbal formula with certain activity against the above syndromes. FNSP has previously been shown to improve clinical symptoms (cough, lumbar and knee weakness, tinnitus) in patients with occupationally related interstitial lung disease. AIM OF THE STUDY: There is a lack of convincing evidence supporting the use of BFNSP for the treatment of COPD. This study aimed to investigate the effect of BFNSP on COPD and explore its underlying mechanisms. MATERIALS AND METHODS: Liquid chromatography-mass spectrometry (LC/MS) was used to analyze the main components of BFNSP and BFNSP-containing serum. A COPD rat model was generated, and the rats were treated with different doses of BFNSP. Lung function indices were analyzed by a pulmonary function testing system, and lung histopathology was assessed by HE staining and scanning electron microscopy. The levels of TGF-β1, IL-6, IL-8, IL-1β, MMP3, MMP-9, and TIMP1 in BALF and the levels of MMP3, MMP-9, TIMP1, and HA in serum were detected by ELISA. Immunohistochemical staining was performed to determine the expression of Col-I, Col-III, and LN in lung tissues. RT‒qPCR was performed to detect the mRNA expression of PI3K, Akt, HIF-1α, MMP-9, TGF-β1, TIMP1, and ERK1/2 in lung tissue, and Western blotting was performed to detect the protein expression of PI3K, p-PI3K, Akt, p-Akt, HIF-1α, MMP-9, TGF-β1, TIMP1, and p-ERK1/2 in lung tissue. In addition, in vitro cellular assays were performed for validation. RESULTS: The results showed that BFNSP effectively improved the functional status of pulmonary ventilation, attenuated pathological damage in lung tissue, inhibited the release of inflammatory factors, reduced extracellular matrix deposition, and inhibited the activation of the PI3K/AKT/HIF-1 signaling pathway in lung tissue in COPD rats (P<0.05) and may alleviate COPD progression by inhibiting the PI3K/AKT/HIF-1 signaling pathway. CONCLUSION: BFNSP inhibits the PI3K/AKT/HIF-1 signaling pathway to regulate extracellular matrix deposition and improve COPD progression.
引用
- Xinchong P, Changxi Z, Anni Z, et al. The Bufei Nashen pill inhibits the PI3K/AKT/HIF-1 signaling pathway to regulate extracellular matrix deposition and improve COPD progression. J Ethnopharmacol. 2024. PMID: 38823661. doi:10.1016/j.jep.2024.118390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。